Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
PMC 7601760
Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma
Whether this carries clinical significance requires longer-term cardiovascular outcome data that is not yet available
* In Methemoglobinemia: Methylene Blue acts by reacting within RBC to form leukomethylene blue, which is a reducing agent of oxidized hemoglobin converting the ferric ion (fe+++) back to its oxygen-carrying ferrous state(fe++)
Durham said that he voted no because of poor characterization of the compound and the potential risk with carcinogenicity. William Zamboni, a pharmacologist at the University of North Carolina said that he voted no because he felt there was a significant lack of data on the safety of the product.
The good news is that this peptide is available to qualified researchers as a reference material
US$ 23.82
US$ 22.89
US$ 25.44
US$ 27.09
US$ 25.33
US$ 23.50
